250results about "Blood cell cancer vaccine" patented technology

Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.

The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.

The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.

Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.

An effective cancer cell vaccine for canines has been developed. The vaccine is prepared from autologous lymphoma cells transfected with emm55. Once an animal is vaccinated, the expressed Emm55 antigen stimulates an immunogenic response to the tumor cells resulting in significantly increased survival, strong autologous and cross reactive humoral and cell mediated responses in several breeds of dogs diagnosed with later stage lymphomas.

The invention relates to the field of biological medicine, in particular to a preparation method for obtaining immune cell exosome carrying a CAR through separation. Specifically CAR immune cell is activated through specific antigen, produced exosome is further analyzed, separated, purified and enriched, and finally the immune cell exosome carrying the CAR is obtained. The exosome can be applied to the treatment of various diseases, such as cancer and severe infectious diseases, overcomes adverse reactions, such as immune inflammation storm, during CAR cell therapy, enhances the CAR tissue infiltration capacity, further has the advantages of high convenience in storage and transportation, and provides a novel strategy for the treatment of relevant diseases.

The present invention relates to methods of inducing and maintaining an immune response against a B-cell idiotype in a subject using an autologous anti-idiotypic vaccine. In one embodiment, the immune response is induced and maintained for treatment of a B-cell derived malignancy selected from among non-Hodgkin's lymphoma. Hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma, and mantle cell lymphoma.

The invention belongs to the technical field of gene engineering, and particularly relates to an anti-BCMA antigen CAR and an expression vector, a CAR cell and application thereof. The CAR comprises an antigen recognition region capable of recognizing a BCMA antigen, a hinge region, a transmembrane region and an intracellular signal domain. The antigen recognition region for recognizing the BCMA antigen is an anti-BCMA single-chain antibody, wherein the heavy-chain amino acid sequence of the antigen recognition region is shown as any one of SEQ ID NO: 1-5, and the light-chain amino acid sequence of the antigen recognition region is shown as any one of SEQ ID NO: 6-10. The CAR can be stably expressed in patient-derived T lymphocytes, has better capability of removing tumor cells, and can beused for adoptive cell therapy aiming at hematological malignancies in preparation of drugs for treating hematological malignancies. The anti-BCMA antigen CAR cell not only can effectively remove tumor target cells expressing the BCMA antigen, but also has no toxic effect on negative antigen, namely tumor cells not expressing the BCMA, so that the safety is very high.

The invention discloses a double-target chimeric antigen receptor targeting an NKG2D ligand and CD19 as well as an expression vector and an application thereof, which belong to the field of tumor immune drugs. The double-target chimeric antigen receptor comprises a signal peptide, a NKG2D extracellular region of a targeted NKG2D ligand, a connecting fragment, a single-chain antibody of the targeted CD19, a lengthened CD8 alpha hinge region, a transmembrane region, a costimulatory factor and an intracellular signal peptide which are connected in sequence; the double-target chimeric antigen receptor can be used for specifically identifying tumor cells expressed by two single targets, namely a targeted NKG2D ligand or a CD19 antigen; in addition, tumor cells co-expressed by the targeting NKG2D ligand and the CD19 antigen can be recognized, the double-target CAR-T has stronger anti-tumor activity, immune escape of positive tumor cells expressed by low-abundance antigen can be avoided, andthus the recurrence risk is reduced.

The present invention provides methods of use for compositions comprising an immunotherapeutic such as chimeric antigen receptor T cells (CAR-T cells), and specifically those that target a tumor antigen cleaved by gamma secretase, in combination with bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof;

for treating lymphomas.

The invention provides a chimeric antigen receptor T cell and application thereof. The chimeric antigen receptor T cell expresses chimeric antigen receptors targeting CD19 and PD-L1 at the same time.The chimeric antigen receptor T cell expresses a CD19 CAR structure and a PD-L1 CAR structure at the same time, and after PD-L1 CAR is combined with PD-L1 expressed by a tumor cell, an activation signal can be transmitted intracellularly. Therefore, the chimeric antigen receptor T cell not only can recognize the tumor cells expressing CD19 in a targeted manner, but also can relieve immunosuppression of PD-1 expressed by the tumor cells on the T cells, avoid an immune escape mechanism of the tumor cells and relieve the problem of drug resistance of CAR-T treatment; and a new idea is provided for CAR-T treatment and adoptive feedback immune cell treatment.

NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to remove checkpoint inhibitory receptor expression and/or add mutant (variant) TRAIL ligand expression.

The invention provides a CD22 protein targeting antibody, a chimeric antigen receptor and a drug, and relates to the technical field of cellular immunotherapy. The chimeric antigen receptor has an antigen binding domain aiming at a tumor surface antigen CD22, and the amino acid sequence of a heavy chain variable region of the antigen binding domain is shown as SEQ ID NO.3; the amino acid sequenceof a light chain variable region of the antigen binding domain is shown as SEQ ID NO. 7. The chimeric antigen receptor can target a CD22 protein; T cells prepared from the chimeric antigen receptor can specifically act on CD22 positive target cells, have very good specificity and sustainability, are high in killing capacity and small in side effect on healthy tissues, and can be used for preparingmedicines for treating or preventing CD22 positive tumors.

The invention discloses features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.

The invention discloses a construction method and an application of a recombinant gene of a bispecific chimeric antigen receptor for treating HIV infection complicated with blood tumor. The chimeric antigen receptor is formed by sequentially connecting a signal peptide, an HIV gp120 antigen specific single-chain antibody and an anti-CD19 single-chain antibody and then sequentially connecting witha CD28 transmembrane region, a CD28 intracellular structural domain (ICD), a 4-1BB costimulatory structural domain and a CD3zeta intracellular signal transduction structural domain in series, or the chimeric antigen receptor comprises: first CAR composed of the signal peptide, the chimeric antigen receptor, the HIV gp120 antigen specific single-chain antibody, the CD28 transmembrane region, the CD28-ICD, the anti-CD19 single-chain antibody, the CD8 transmembrane region, the CD28-ICD, the 4-1BB costimulatory structural domain and the CD3zeta intracellular signal transduction domain; and secondCAR composed of and the signal peptide, the anti-CD19 single-chain antibody, the CD8 transmembrane region in parallel, connecting the CD28-ICD, the 4-1BB costimulatory structural domain and the CD3zeta intracellular signal transduction domain, wherein the first CAR and the second CAR are sequentially connected in parallel.

The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens.

The disclosure relates to an engineered immune cell and use thereof. The engineered immune cell provided in the disclosure comprises a CAR or engineered TCR, which CAR or engineered TCR can comprise a first antigen binding domain and a second antigen binding domain. The engineered immune cells, when administered into a subject, can inhibit the host immune cells such as T cells and/or NK cells and enhance the survival and persistence of the engineered immune cells in vivo, thereby exhibiting more effective tumor killing activity.